• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia.

作者信息

Lee Julia S, Wagner Charlotte B, Prelewicz Stacy, Kurish Heena P, Walchack Robert, Cenin Danielle A, Patel Seema, Lo Mimi, Schlafer Danielle, Li Belinda K T, Donald Harvey Iii R, Wasef Bestis, Ying Jian, Kovacsovics Tibor

机构信息

Department of Pharmacy, Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT.

Department of Pharmacy, Cleveland Clinic Foundation, Cleveland, OH.

出版信息

Haematologica. 2023 Dec 1;108(12):3460-3463. doi: 10.3324/haematol.2022.281967.

DOI:10.3324/haematol.2022.281967
PMID:37345485
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10690909/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed5e/10690909/9df300137650/1083460.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed5e/10690909/9df300137650/1083460.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ed5e/10690909/9df300137650/1083460.fig1.jpg

相似文献

1
Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in <i>FLT3</I>-mutated acute myeloid leukemia.米哚妥林联合伊达比星及阿糖胞苷诱导治疗FLT3突变型急性髓系白血病的疗效与毒性
Haematologica. 2023 Dec 1;108(12):3460-3463. doi: 10.3324/haematol.2022.281967.
2
Midostaurin in Combination With Standard Chemotherapy for Treatment of Newly Diagnosed FMS-Like Tyrosine Kinase 3 (FLT3) Mutation-Positive Acute Myeloid Leukemia.米哚妥林联合标准化疗治疗新诊断的FMS样酪氨酸激酶3（FLT3）突变阳性急性髓系白血病。
Ann Pharmacother. 2018 Apr;52(4):364-369. doi: 10.1177/1060028017747900. Epub 2017 Dec 12.
3
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.米哚妥林联合化疗治疗伴有FLT3突变的急性髓系白血病
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
4
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.索拉非尼、伊达比星和阿糖胞苷联合治疗 FLT3 突变急性髓系白血病患者的分子反应和复发模式。
Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):361-6. doi: 10.1016/j.clml.2011.06.007.
5
Updated safety of midostaurin plus chemotherapy in newly diagnosed mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.新诊断的 突变阳性急性髓系白血病中米哚妥林联合化疗的更新安全性：RADIUS-X 扩大准入计划。
Leuk Lymphoma. 2020 Dec;61(13):3146-3153. doi: 10.1080/10428194.2020.1805109. Epub 2020 Aug 19.
6
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.索拉非尼、伊达比星和阿糖胞苷联合治疗年轻急性髓系白血病患者的 I/II 期研究。
J Clin Oncol. 2010 Apr 10;28(11):1856-62. doi: 10.1200/JCO.2009.25.4888. Epub 2010 Mar 8.
7
Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.美国新诊断 FLT3 突变型急性髓系白血病中米哚妥林的成本效果分析。
Pharmacoeconomics. 2019 Feb;37(2):239-253. doi: 10.1007/s40273-018-0732-4.
8
The FLT3 Y842D mutation may be highly sensitive to midostaurin: a case report.FLT3 Y842D 突变可能对米哚妥林高度敏感：一例报告。
J Int Med Res. 2022 May;50(5):3000605221097774. doi: 10.1177/03000605221097774.
9
Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.米哚妥林用于治疗新诊断的FLT3突变阳性的成年急性髓系白血病患者。
Drugs Today (Barc). 2017 Oct;53(10):531-543. doi: 10.1358/dot.2017.53.10.2717625.
10
Midostaurin/PKC412 for the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia.米哚妥林/PKC412用于治疗新诊断的FLT3突变阳性急性髓系白血病。
Expert Rev Hematol. 2017 Dec;10(12):1033-1045. doi: 10.1080/17474086.2017.1397510. Epub 2017 Oct 30.

引用本文的文献

1
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real-world practice.一项关于急性髓系白血病中FLT3抑制剂治疗用途和缓解率的GIMEMA调查：来自意大利真实世界实践的见解
EJHaem. 2024 Nov 22;5(6):1274-1277. doi: 10.1002/jha2.1045. eCollection 2024 Dec.
2
Venetoclax Combination Treatment of Acute Myeloid Leukemia in Adolescents and Young Adult Patients.维奈克拉联合治疗青少年和年轻成人急性髓系白血病
J Clin Med. 2024 Apr 1;13(7):2046. doi: 10.3390/jcm13072046.

本文引用的文献

1
Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology.急性髓系白血病，第 3 版 2023 年，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2023 May;21(5):503-513. doi: 10.6004/jnccn.2023.0025.
2
Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses.新发急性髓系白血病的缓解率、无事件生存和总生存：美国食品和药物管理局试验水平和患者水平分析。
J Clin Oncol. 2022 Mar 10;40(8):847-854. doi: 10.1200/JCO.21.01548. Epub 2021 Dec 10.
3
Updated safety of midostaurin plus chemotherapy in newly diagnosed mutation-positive acute myeloid leukemia: the RADIUS-X expanded access program.
新诊断的 突变阳性急性髓系白血病中米哚妥林联合化疗的更新安全性：RADIUS-X 扩大准入计划。
Leuk Lymphoma. 2020 Dec;61(13):3146-3153. doi: 10.1080/10428194.2020.1805109. Epub 2020 Aug 19.
4
Comparison of anthracyclines used for induction chemotherapy in patients with FLT3-ITD-mutated acute myeloid leukemia.用于FLT3-ITD突变型急性髓系白血病患者诱导化疗的蒽环类药物比较。
Leuk Res. 2018 May;68:51-56. doi: 10.1016/j.leukres.2018.03.006. Epub 2018 Mar 8.
5
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation.米哚妥林联合化疗治疗伴有FLT3突变的急性髓系白血病
N Engl J Med. 2017 Aug 3;377(5):454-464. doi: 10.1056/NEJMoa1614359. Epub 2017 Jun 23.
6
Prospective Randomized Comparison of Idarubicin and High-Dose Daunorubicin in Induction Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia.前瞻性随机比较柔红霉素与高三尖杉酯碱在初治急性髓细胞白血病诱导化疗中的作用。
J Clin Oncol. 2017 Aug 20;35(24):2754-2763. doi: 10.1200/JCO.2017.72.8618. Epub 2017 Jun 20.
7
Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia.更高的柔红霉素暴露量对FLT3突变的急性髓系白血病有益。
Blood. 2016 Jul 21;128(3):449-52. doi: 10.1182/blood-2016-04-712091. Epub 2016 Jun 6.
8
Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups.高剂量柔红霉素在急性髓系白血病诱导治疗中的益处涵盖细胞遗传学和分子学分组。
Blood. 2016 Mar 24;127(12):1551-8. doi: 10.1182/blood-2015-07-657403. Epub 2016 Jan 11.